"Antitubercular Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy.
| Descriptor ID |
D000995
|
| MeSH Number(s) |
D27.505.954.122.085.255
|
| Concept/Terms |
Antitubercular Agents- Antitubercular Agents
- Agents, Antitubercular
- Antitubercular Drugs
- Drugs, Antitubercular
- Tuberculostatic Agents
- Agents, Tuberculostatic
|
Below are MeSH descriptors whose meaning is more general than "Antitubercular Agents".
Below are MeSH descriptors whose meaning is more specific than "Antitubercular Agents".
This graph shows the total number of publications written about "Antitubercular Agents" by people in this website by year, and whether "Antitubercular Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 2 | 2 |
| 2010 | 4 | 1 | 5 |
| 2011 | 5 | 1 | 6 |
| 2013 | 2 | 1 | 3 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 1 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 1 | 2 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 1 | 2 |
| 2023 | 0 | 1 | 1 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antitubercular Agents" by people in Profiles.
-
Jama SS, Abdi MM. Tuberculosis treatment outcomes and associated factors among patients treated at Bosaso TB Hospital, Bosaso, Somalia: A five-year retrospective study. PLoS One. 2025; 20(1):e0314693.
-
Moe S, Rekart ML, Hernandez D, Sholpan A, Ismailov A, Oluya M, Bayniyazova A, Zinaida T, Nargiza P, Gomez-Restrepo C, Sitali N, Sinha A. Primary bedaquiline resistance in Karakalpakstan, Uzbekistan. Int J Tuberc Lung Dis. 2023 05 01; 27(5):381-386.
-
Lam E, Schaefer J, Zheng R, Zhan T, Kraft WK. Twice-Daily Doravirine Overcomes the Interaction Effect from Once-Weekly Rifapentine and Isoniazid in Healthy Volunteers. Clin Transl Sci. 2020 11; 13(6):1244-1250.
-
Stokes SS, Vemula R, Pucci MJ. Advancement of GyrB Inhibitors for Treatment of Infections Caused by Mycobacterium tuberculosis and Non-tuberculous Mycobacteria. ACS Infect Dis. 2020 06 12; 6(6):1323-1331.
-
Irfan M, Idrees F, Jabeen K, Zubairi ABS, Butt S, Hasan R. Accuracy of genotype MTBDRplus line probe assay in patients with tuberculous pleural effusion: comparison with clinical and culture based diagnosis. Infect Dis (Lond). 2020 04; 52(4):235-241.
-
Irfan S, Rao N, Irfan M, Iftikhar I, Azizullah Z, Jabeen K, Hasan R. Utility of the microcolony method for evaluation of multidrug-resistant tuberculosis patients in Karachi, Pakistan. Int J Tuberc Lung Dis. 2019 07 01; 23(7):838-843.
-
Idrees F, Irfan M, Jabeen K, Farooqi J, Hasan R. Diagnostic performance of genoType? MTBDRplus line probe assay in bronchoalveolar lavage for pulmonary tuberculosis diagnosis in sputum scarce and smear-negative patients. Int J Mycobacteriol. 2017 Apr-Jun; 6(2):122-126.
-
Vaid U, Kane GC. Tuberculous Peritonitis. Microbiol Spectr. 2017 01; 5(1).
-
Shakoor S, Tahseen S, Jabeen K, Fatima R, Malik FR, Rizvi AH, Hasan R. Fluoroquinolone consumption and -resistance trends in Mycobacterium tuberculosis and other respiratory pathogens: Ecological antibiotic pressure and consequences in Pakistan, 2009-2015. Int J Mycobacteriol. 2016 12; 5(4):412-416.
-
Jabeen K, Shakoor S, Hasan R. Fluoroquinolone-resistant tuberculosis: implications in settings with weak healthcare systems. Int J Infect Dis. 2015 Mar; 32:118-23.